Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Infliximab
Therapeutic Area : Gastroenterology
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
ZYMFENTRA™ Shows Long-Term Efficacy for Crohn's Disease and Ulcerative Colitis Treatment
Details : Zymfentra (infliximab) a TNF alpha inhibitor, is the first and only FDA-approved SC formulation, for adults with moderately to severely active ulcerative colitis and crohn’s disease.
Brand Name : Zymfentra
Molecule Type : Large molecule
Upfront Cash : Not Applicable
May 21, 2024
Lead Product(s) : Infliximab
Therapeutic Area : Gastroenterology
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Infliximab
Therapeutic Area : Gastroenterology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Health Canada Approves Remsima™ SC for the Treatment of Inflammatory Bowel Disease (IBD)
Details : Remsima (infliximab) blocks the action of TNF-alpha. It is approved for maintenance therapy in adults with moderately to severely active ulcerative colitis and crohn’s disease.
Brand Name : Remsima
Molecule Type : Large molecule
Upfront Cash : Not Applicable
February 18, 2024
Lead Product(s) : Infliximab
Therapeutic Area : Gastroenterology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Infliximab
Therapeutic Area : Gastroenterology
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : CT-P13 SC is the world’s first subcutaneous formulation of infliximab. A 120 mg fixed dose of CT-P13 SC has been approved for use in the European Union (EU), in adults regardless of body weight, in both existing and newly added indications.
Brand Name : Remsima
Molecule Type : Large molecule
Upfront Cash : Not Applicable
December 22, 2022
Lead Product(s) : Infliximab
Therapeutic Area : Gastroenterology
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Infliximab
Therapeutic Area : Neurology
Study Phase : Preclinical
Sponsor : National Institute for Health and Care Research
Deal Size : Undisclosed
Deal Type : Funding
Details : Under a prior Memorandum of Understanding, the anti-TNF infliximab, Remsima (a biosimilar of Remicade), approved for use in the U.K., will be supplied for trial by Celltrion Healthcare UK Limited. The University of Oxford and Celltrion are currently comp...
Brand Name : Remsima
Molecule Type : Large molecule
Upfront Cash : Undisclosed
July 27, 2022
Lead Product(s) : Infliximab
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Sponsor : National Institute for Health and Care Research
Deal Size : Undisclosed
Deal Type : Funding
Lead Product(s) : Infliximab
Therapeutic Area : Gastroenterology
Study Phase : Preclinical
Sponsor : SGS Life Sciences
Deal Size : Undisclosed
Deal Type : Collaboration
SGS’s Quay Pharma Collaborates to Develop New Oral Medicine for Inflammatory Bowel Disease
Details : Formulating infliximab as an oral capsule – which must survive the digestive system's harsh environment and reach the colon intact – is transformational.
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : Undisclosed
July 18, 2022
Lead Product(s) : Infliximab
Therapeutic Area : Gastroenterology
Highest Development Status : Preclinical
Sponsor : SGS Life Sciences
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Infliximab
Therapeutic Area : Immunology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Results Remsima (infliximab), showed a statistically significant difference in favour of SC compared to IV-treated patients at week 30 in almost all clinical variables, including low disease activity rates and remission rate.
Brand Name : Remsima
Molecule Type : Large molecule
Upfront Cash : Not Applicable
June 01, 2022
Lead Product(s) : Infliximab
Therapeutic Area : Immunology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Infliximab
Therapeutic Area : Gastroenterology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Data from the RTDM study show infliximab drug levels are stable across a 14-day treatment cycle for Crohn’s disease patients in remission, under maintenance therapy with Remsima SC, enabling therapeutic drug monitoring to be performed at any time betwe...
Brand Name : Remsima
Molecule Type : Large molecule
Upfront Cash : Not Applicable
February 18, 2022
Lead Product(s) : Infliximab
Therapeutic Area : Gastroenterology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Infliximab
Therapeutic Area : Musculoskeletal
Study Phase : Phase II/ Phase III
Sponsor : Celltrion
Deal Size : Undisclosed
Deal Type : Agreement
Details : Under the MOU with Celltrion Healthcare, supply of anti-TNF biosimilar drug used in the ongoing development for new indications including the first antibody biosimilar, Remsima®, infliximab for major autoimmune disorders such as rheumatoid arthritis and...
Brand Name : Remsima
Molecule Type : Large molecule
Upfront Cash : Undisclosed
September 20, 2021
Lead Product(s) : Infliximab
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase II/ Phase III
Sponsor : Celltrion
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Infliximab
Therapeutic Area : Immunology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Remsima™ SC is the first and only subcutaneous form of infliximab to patients, payers and clinicians in Canada. Remsima™ SC offers an innovative treatment option for patients living with chronic inflammatory conditions in Canada.
Brand Name : Remsima
Molecule Type : Large molecule
Upfront Cash : Not Applicable
June 07, 2021
Lead Product(s) : Infliximab
Therapeutic Area : Immunology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Infliximab
Therapeutic Area : Immunology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The recommended new posology is to start Remsima® SC 120mg weekly up to week 4 and inject every 2 weeks thereafter; For patients currently on infliximab IV, Remsima® SC can be administered after 8 weeks from last dose without additional IV loading.
Brand Name : Remsima
Molecule Type : Large molecule
Upfront Cash : Not Applicable
March 31, 2021
Lead Product(s) : Infliximab
Therapeutic Area : Immunology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?